# Cosiporfin Sodium for Injection Photodynamic Therapy

> **NCT07398339** · PHASE2 · RECRUITING · sponsor: **Shanghai Guangsheng Biopharmaceutical Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Biliary Tract Cancers (BTC)

## Interventions

- **DRUG:** Cosiporfin Sodium for injection, DVDMS
- **DRUG:** Gemcitabine Hydrochloride for Injection
- **DRUG:** Cisplatin for injection

## Key facts

- **NCT ID:** NCT07398339
- **Lead sponsor:** Shanghai Guangsheng Biopharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07398339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07398339, "Cosiporfin Sodium for Injection Photodynamic Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07398339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*